Testing the Addition of an Anti-cancer Drug, Hu5F9-G4 (Magrolimab), to the Usual Chemotherapy Treatment (Mogamulizumab) in T-Cell (a Type of Immune Cell) Lymphoma That Has Returned After or Does Not Respond to Treatment

Conditions:   Recurrent Mycosis Fungoides;   Recurrent Mycosis Fungoides and Sezary Syndrome;   Refractory Mycosis Fungoides;   Refractory Mycosis Fungoides and Sezary Syndrome;   Sezary Syndrome;   Stage IB Mycosis Fungoides and Sezary Syndrome AJCC v8;   Stage II Mycosis Fungoides and S ezary Syndrome AJCC v8;   Stage IIA Mycosis Fungoides and Sezary Syndrome AJCC v8;   Stage IIB Mycosis Fungoides and Sezary Syndrome AJCC v8;   Stage III Mycosis Fungoides and Sezary Syndrome AJCC v8;   Stage IIIA Mycosis Fungoides and Sezary Syndrome AJCC v8;   Stage IIIB Mycosis Fungoides and Sezary Syndrome AJCC v8;   Stage IV Mycosis Fungoides and Sezary Syndrome AJCC v8;   Stage IVA1 Mycosis Fungoides and Sezary Syndrome AJCC v8;   Stage IVA2 Mycosis Fungoides and Sezary Syndrome AJCC v8;   Stage IVB Mycosis Fungoides and Sezary Syndrome AJCC v8 Interventions:   Biological: Magrolimab;   Biological: Mogamulizumab Sponsor:   National Cancer Institute (NCI) Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials